摘要
目的探讨子宫内膜异位症(EMs)患者手术前后肿瘤特异性生长因子(TSGF)、糖类抗原125(CA125)、血管内皮生长因子(VEGF)水平的变化,以及其与EMs临床分期和复发的关系。方法选取经手术确诊的EMs患者110例为研究对象,检测患者术前、术后1、3、6个月、1年时血清TSGF、CA125及血浆VEGF水平,并进行比较。结果术后3个月,3项指标均较术前下降(均P<0.05)。EMsⅣ期患者术前TSGF、VEGF水平均较Ⅲ期患者升高(均P<0.05)。术后1年,EMs复发患者TSGF、VEGF水平均明显高于未复发者(均P<0.05),而CA125水平与未复发者比较无统计学差异(P>0.05)。结论 TSGF、CA125、VEGF均可用于评价EMs治疗效果;重度EMs患者较轻度EMs患者TSGF、VEGF水平高。
Objective To investigate the serum tumor specific growth factor （TSGF）, CA125 and plasma vascular endothelial growth factor（VEGF） levels in patients with endometriosis（EMs） and their clinical significance. Methods One hundred and ten patients with endometriosis receiving surgical treatment in our hospital were enrolled in the study. Serum TSGF, CA125 and plasma VEGF levels were measured before treatment and 1, 3, 6 and 12 months after treatment. Results Serum TSGF, CA125 and plasma VEGF levels were decreased 3 months after operation compared to the levels before treatment. Serum TSGF, CA125 and plasma VEGF levels inⅢ /Ⅳstage cases were higher than those in Ⅰ/Ⅲ stage cases; and there was significant difference between stage Ⅲ and stage IV patients. The serum TSGF and plasma VEGF levels in 5 cases relapsed after 12 month were higher than those non-relapsed ones; while no difference in serum CA125 level. Conclusion Combined detection of serum TSGF, CA125 and plasma VEGF may be of value in diagnosis of EMS and monitoring the therapeutic efficacy of patients.
出处
《浙江医学》
CAS
2016年第9期636-638,共3页
Zhejiang Medical Journal
基金
2010年度舟山市科技计划项目(10144)
